Sugi Predict

Sugi Predict / Compounds / SCHEMBL4163085

SCHEMBL4163085

SCHEMBL4163085

CC1(C)OB(c2cncc(O)c2)OC1(C)C

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 1/20 0.40
▸ F11 P03951 1/20 0.38
▸ LPL P06858 11/20 0.38
▸ LIPG Q9Y5X9 11/20 0.38
▸ GSK3A P49840 1/20 0.35
▸ GSK3B P49841 1/20 0.35
▸ PDGFRB P09619 1/20 0.34
▸ KDR P35968 1/20 0.34
▸ P2RX7 Q99572 1/20 0.34
▸ DGAT1 O75907 2/20 0.33
▸ IRAK4 Q9NWZ3 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA9 Q16790 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15650037 0.91 FFAR1 (0.35) FFAR1F11LPLLIPGGSK3A
SCHEMBL12373176 0.86 LPL (0.44) FFAR1F11LPLLIPGP2RX7
SCHEMBL20043543 0.79 LPL (0.39) FFAR1F11LPLLIPGGSK3A
SCHEMBL626260 0.79 LPL (0.39) FFAR1F11LPLLIPGGSK3A
SCHEMBL31219289 0.79 LPL (0.39) FFAR1F11LPLLIPGGSK3A
SCHEMBL16426120 0.78 LPL (0.44) FFAR1F11LPLLIPGP2RX7
SCHEMBL28628663 0.78 LPL (0.44) FFAR1F11LPLLIPGCA1
SCHEMBL925705 0.78 LPL (0.38) FFAR1F11LPLLIPGGSK3A
SCHEMBL791063 0.78 F11 (0.38) FFAR1F11LPLLIPGGSK3A
SCHEMBL1302755 0.78 LPL (0.38) FFAR1F11LPLLIPGGSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12527797-B2 Isochromene derivatives as phosphoinositide 3-kinases inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2026-01-20 — — US disclosed
EP-4605089-A1 COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K Mekanistic Therapeutics LLC (US) 2025-08-27 — — EP disclosed
US-20240246992-A1 MACROCYCLIC LRRK2 KINASE INHIBITORS SERVIER LAB (FR) 2024-07-25 — — US disclosed
US-20240132431-A1 METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-04-25 — — US disclosed
WO-2024086296-A1 COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K MEKANISTIC THERAPEUTICS LLC (US) 2024-04-25 — — WO disclosed
US-20240116948-A1 PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-04-11 — — US disclosed
EP-4308570-A1 MACROCYCLIC LRRK2 KINASE INHIBITORS Les Laboratoires Servier (FR) 2024-01-24 — — EP disclosed
CN-117425661-A Macrocyclic LRRK2 kinase inhibitors 法国施维雅药厂 2024-01-19 — — CN disclosed
EP-4279476-A1 METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-11-22 — — EP disclosed
EP-4279476-A1 METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-11-22 — — EP disclosed
WO-2014060431-A1 PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS ALMIRALL, S.A. (ES) 2014-04-24 — — WO disclosed
WO-2014060432-A1 PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS ALMIRALL, S.A. (ES) 2014-04-24 — — WO disclosed
US-8314112-B2 Pyrrolopyrimidines and pyrrolopyridines NOVARTIS AG (CH) 2012-11-20 — — US disclosed
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 — — US disclosed
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 — — US disclosed
EP-2366699-A1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2011-09-21 — — EP disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 — — US disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 — — US disclosed
WO-2010038465-A1 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF 旭化成ファーマ株式会社 (JP) 2010-04-08 — — WO disclosed
US-20090181941-A1 Pyrrolopyrimidines and Pyrrolopyridines NOVARTIS AG (CH) 2009-07-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246992-A1 MACROCYCLIC LRRK2 KINASE INHIBITORS LRRK2, PARK7, PINK1 FFAR1 3707/4885F11 4233/4885LPL 2522/4885
US-20240116948-A1 PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS TGFBR1, ACVR1, TGFBR2 FFAR1 664/4885F11 2706/4885LPL 3349/4885
US-12527797-B2 Isochromene derivatives as phosphoinositide 3-kinases inhibitors PIK3R5, PIK3CD, PIK3R4 FFAR1 2637/4885F11 4056/4885LPL 2034/4885
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof RELA, NFKBIA, NFKB2 FFAR1 2209/4885F11 4605/4885LPL 3942/4885
US-20090181941-A1 Pyrrolopyrimidines and Pyrrolopyridines ALK, ACVR1, PTPN4 FFAR1 222/4885F11 2017/4885LPL 2217/4885
US-20240132431-A1 METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP MGMT, MCL1, FANCF FFAR1 1370/4885F11 1213/4885LPL 4674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.